Bausch + Lomb Reports Phase 2 Findings for BL1332 in Post-Surgical Ocular Pain
Bausch + Lomb (BLCO) reported Phase 2 results for BL1332, a topical TRPV1 antagonist for post-surgical ocular pain. While the primary endpoint at 24 hours was not met, both doses showed numerically greater pain relief than the vehicle. Exploratory analyses indicated faster corneal healing. The company plans to discuss findings with the FDA and potentially plan Phase 3 trials.
How this was made

The 30-second read
Why it matters
The key trading question is whether the missed primary endpoint meaningfully undermines the program or whether the consistent directional improvements and healing signals justify Phase 3 planning. The company’s stated intent to discuss study design and endpoints with FDA suggests an active mitigation path.
Market read
A Phase 2 clinical readout with a missed primary endpoint but supportive secondary and exploratory signals can shift probability-weighting for Phase 3 success and near-term pipeline valuation.
What to watch
The article provides limited detail on effect size consistency, multiplicity adjustments, and how SPID relates to patient-relevant outcomes. Traders may discount the nominal secondary significance and focus on endpoint redesign feasibility with FDA.
Background
BL1332 is a first-in-class topical TRPV1 antagonist being studied for ocular surface pain after PRK surgery; this is a Phase 2 topline readout with vehicle control.
Ticker impact
Bausch + Lomb reported Phase 2 topline results for BL1332, including failure to meet the 24-hour primary SPID endpoint and FDA discussion plans.
Shares may face near-term skepticism due to the missed primary endpoint, partially offset by supportive exploratory and secondary signals plus stated FDA Phase 3 planning.
The article explicitly states the primary endpoint at 24 hours was not met, while also highlighting numerically better pain relief across analyses, nominal significance in a secondary window, and faster corneal healing signals. That combination typically reduces conviction for immediate re-rating but supports continued development optionality.
Market effects
Adds another data point for ocular pain/TRPV1 antagonist development risk, potentially influencing sentiment around ophthalmic pain pipeline programs.
Limited direct regional impact; clinical-trial read-through is mostly US-listed biotech/healthcare sentiment.
Moderate global relevance for ophthalmology R&D investors, but not a broad macro or sector-wide catalyst.
Counterpoint
The primary endpoint miss may be less damaging if the exploratory complete pain relief and corneal healing signals are clinically meaningful and can be translated into a revised Phase 3 endpoint strategy with FDA.
Key entities
- companyBausch + Lomb Corporation
Reported Phase 2 topline results for BL1332 in post-PRK ocular pain and outlined next steps with FDA, including potential Phase 3 planning.
- drug_candidateBL1332
Topical TRPV1 antagonist evaluated at 0.30% and 0.15% versus vehicle in a randomized Phase 2 PRK pain study.
- regulatorU.S. Food and Drug Administration (FDA)
Will be engaged to align on future development, including potential Phase 3 planning and endpoint/study design adjustments.


